|
Jan 9
|
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
|
|
Dec 20
|
Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 10
|
Akebia Therapeutics (NASDAQ:AKBA) shareholders have earned a 265% return over the last year
|
|
Dec 1
|
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Dec 1
|
Top Penny Stocks for Q4 2023
|
|
Nov 9
|
Q3 2023 Akebia Therapeutics Inc Earnings Call
|
|
Nov 8
|
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
|
|
Nov 2
|
Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors
|
|
Oct 18
|
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023
|
|
Aug 10
|
Akebia Therapeutics Provides Update on Form 10-Q Filing
|
|
Apr 25
|
Akebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
|